Satsuma Pharmaceuticals Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 16

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $30M

Satsuma Pharmaceuticals General Information

Description

Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 4819 Emperor Boulevard
  • Suite 340
  • Durham, NC 27703
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Vertical(s)
Corporate Office
  • 4819 Emperor Boulevard
  • Suite 340
  • Durham, NC 27703
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Satsuma Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 08-Jun-2023 $30M Completed Clinical Trials - General
5. PIPE 31-Mar-2021 Completed Clinical Trials - General
4. IPO 13-Sep-2019 Completed Clinical Trials - General
3. Early Stage VC (Series B) 24-Apr-2019 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 12-Feb-2018 $12.1M $12.1M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Satsuma Pharmaceuticals’s complete valuation and funding history, request access »

Satsuma Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Satsuma Pharmaceuticals’s complete cap table history, request access »

Satsuma Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic prod
Drug Discovery
Durham, NC
16 As of 2023

Cary, NC
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Satsuma Pharmaceuticals Competitors (11)

One of Satsuma Pharmaceuticals’s 11 competitors is Heron Therapeutics, a Formerly VC-backed company based in Cary, NC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Heron Therapeutics Formerly VC-backed Cary, NC
Voyager Therapeutics Formerly VC-backed Lexington, MA
OptiNose Private Equity-Backed PA
IPI Legacy Liquidation Formerly VC-backed Seattle, WA
Centrexion Therapeutics Venture Capital-Backed Boston, MA
You’re viewing 5 of 11 competitors. Get the full list »

Satsuma Pharmaceuticals Patents

Satsuma Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3122396-A1 Compositions, devices, and methods for treating or preventing headaches Active 11-Dec-2018
EP-3893877-A1 Compositions, devices, and methods for treating or preventing headaches Pending 11-Dec-2018
EP-3893877-A4 Compositions, devices, and methods for treating or preventing headaches Pending 11-Dec-2018
GB-2581431-A Compositions, devices, and methods for treating or preventing headaches Inactive 11-Dec-2018
US-10758532-B2 Compositions, devices, and methods for treating or preventing headaches Active 11-Dec-2018 A61K31/48
To view Satsuma Pharmaceuticals’s complete patent history, request access »

Satsuma Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Satsuma Pharmaceuticals Former Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
CAM Capital Asset Manager Minority
Citadel Enterprise Americas Hedge Fund Minority
Commodore Capital Venture Capital Minority
Cormorant Asset Management PE/Buyout Minority
Eventide Asset Management Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Satsuma Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Satsuma Pharmaceuticals’s complete esg history, request access »

Satsuma Pharmaceuticals FAQs

  • When was Satsuma Pharmaceuticals founded?

    Satsuma Pharmaceuticals was founded in 2016.

  • Where is Satsuma Pharmaceuticals headquartered?

    Satsuma Pharmaceuticals is headquartered in Durham, NC.

  • What is the size of Satsuma Pharmaceuticals?

    Satsuma Pharmaceuticals has 16 total employees.

  • What industry is Satsuma Pharmaceuticals in?

    Satsuma Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Satsuma Pharmaceuticals a private or public company?

    Satsuma Pharmaceuticals is a Private company.

  • What is the current valuation of Satsuma Pharmaceuticals?

    The current valuation of Satsuma Pharmaceuticals is .

  • What is Satsuma Pharmaceuticals’s current revenue?

    The current revenue for Satsuma Pharmaceuticals is .

  • How much funding has Satsuma Pharmaceuticals raised over time?

    Satsuma Pharmaceuticals has raised $237M.

  • Who are Satsuma Pharmaceuticals’s investors?

    CAM Capital, Citadel Enterprise Americas, Commodore Capital, Cormorant Asset Management, and Eventide Asset Management are 5 of 15 investors who have invested in Satsuma Pharmaceuticals.

  • Who are Satsuma Pharmaceuticals’s competitors?

    Heron Therapeutics, Voyager Therapeutics, OptiNose, IPI Legacy Liquidation, and Centrexion Therapeutics are some of the 11 competitors of Satsuma Pharmaceuticals.

  • When was Satsuma Pharmaceuticals acquired?

    Satsuma Pharmaceuticals was acquired on 08-Jun-2023.

  • Who acquired Satsuma Pharmaceuticals?

    Satsuma Pharmaceuticals was acquired by Shin Nippon Biomedical Laboratories.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process